Adeona Pharmaceuticals, Inc.Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company’s primary strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is preparing to make reaZinTM, a prescription medical food for the dietary management of zinc deficiency associated with Alzheimer’s disease, commercially available. In addition, the Company is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and age-related macular degeneration. For more information, please visit Adeona’s website at www.adeonapharma.com. Request email alerts and additional information |
|
KCSA Strategic Communications
Garth Russell
Managing Director
OP: 212-896-1250
- 09 Feb 2012 : Adeona CEO to Present at the Harvard Investors Group Forum
- 19 Jan 2012 : Adeona Announces Initiation of Phase II Clinical Trial of Trimestaâ„¢ for Cognitive Dysfunction in Multiple Sclerosis
- 21 Dec 2011 : Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development
- 12 Oct 2011 : Adeona Senior Vice President of Research & Development to Present at International Scientific Conference
- 05 Oct 2011 : Adeona CEO to Present at the NYC Medtech Forum